Fellow 1988-1990

Research Interests
Signalling pathways in cancer and normal cells; insulin signalling and its defects in type II diabetes; mechanisms of insulin action and of glucose uptake and resistance; insulin secretion and its control. Mitochondrial metabolism, its regulation, control and functions of intracellular and intramitochondrial calcium.

Drug discovery.

Other Information
Resigned fellowship 30.9.90 on appointment as Head of Biochemical Pharmacology, Syntex Research Centre, Heriot-Watt University, Edinburgh
Awarded DSc, University of Bristol, 1992
Visiting Professor, University of Sunderland, 1994
Appointed Head of Diabetes Biology Department, Novo Nordisk, A/S, Denmark, from 1.11.95
Made Director of Diabetes Discovery, 1996
Elected a Member of the Institute, 1996
Director of Target Cell Biology, Novo Nordisk, 1998
Vice President, Target Cell Biology, Novo Nordisk, 2000
Appointed Vice President for Discovery Research UK, OSI Pharmaceuticals from 1.6.02
Vice President for Research, Prosidion from 1.12.04
Chief Scientific Officer (from 1.12.04) and Senior Vice President for Research (from 1.7.07) at (OSI) Prodidion until 31.12.08
Co-founded McC+R&D Consulting Ltd with Dr C Reynet, December 2009